Odyssey Therapeutics is preparing a second attempt at an initial public offering after withdrawing its first try a year earlier. The Boston-based company filed for the IPO again, aiming to take advantage of what it calls a “warmer” market. The move suggests Odyssey sees room for better execution conditions—an important consideration for clinical-stage biotechs where valuation and syndicate appetite can swing rapidly. For investors, the filing adds another candidate in the pipeline of new listings competing for attention. While the report does not detail the equity terms, the IPO resubmission itself indicates continued funding needs tied to ongoing development and potential data milestones.